Reward Learning May Be an Important Familial Marker in Schizophrenia
Patients with schizophrenia spectrum disorder and their relatives may have a general reduced sensitivity to reward, indicating that reward learning may be an important familial marker in schizophrenia...
View ArticleIdentifying the Clinical Determinants of Fever in Clozapine Treatment
Fever induced by clozapine has an incidence of between 0.5% to 55%, and is a frequent side effect that usually occurs during the first 4 weeks of treatment.¹ In clozapine users, fever may be a warning...
View ArticleSecond-Generation Antipsychotics as Targeted Treatment in Schizophrenia
Treatment with different second-generation antipsychotic agents, including risperidone, olanzapine, quetiapine, and aripiprazole, is associated with differing profiles of 5-HT2A and 5-HT6 receptor...
View ArticleOscillatory Electroencephalography Biomarkers May Improve Cognition in...
Event-related and oscillatory electroencephalography (EEG) biomarkers have been demonstrated to predict full-course treatment gains in focal and global cognitive ability in treatment refractory...
View ArticleCortical Volumetric Asymmetry Development and Increased Psychosis Risk
In individuals at clinical high risk (CHR) for psychosis, cortical volumetric asymmetry (CVA) development over time reflects the increased risk for psychosis and schizophrenia, according to study...
View ArticleLack of Insight Mediates Cognitive Impairment Awareness, Schizophrenia Symptoms
Lack of insight may play a central role in mediating the relationship between cognitive impairment awareness and schizophrenia symptoms, according to research published in the European Archives of...
View ArticleAbnormal CRP May Be a Biomarker of Major Depression in Schizophrenia
Major depressive disorder (MDD) occurs frequently in individuals with schizophrenia, and increased levels of C-reactive protein (CRP) in this population were found to be significantly associated with...
View ArticleDisparities in Care Identified in Individuals With Schizophrenia and Cancer
Disparities in health care were identified in patients with cancer and schizophrenia receiving care at end of life compared with patients with cancer who do not have a mental illness, according to a...
View ArticleFew Grey Matter Abnormalities Found in Individuals at Clinical High-Risk for...
Although individuals at clinical high-risk (CHR) for schizophrenia may not demonstrate comprehensive abnormalities in cortical grey matter, small to moderate correlations have been observed between...
View ArticleImproving Treatment Adherence in Schizophrenia: Long-Acting Injectables
Poor treatment adherence is a consistent challenge in the management of schizophrenia, with recent findings showing nonadherence rates of 26.5% to 68.8% among patients receiving oral antipsychotic...
View ArticleDepression Affects Self-Assessment of Social Function
Self-reported interpersonal functioning is determined by current level of depression, both in patients with schizophrenia and in healthy control individuals. In a recent study published in Psychiatry...
View ArticleFirst-Episode Schizophrenia and Relapses After Antipsychotic Discontinuation
Relapse rates are high after discontinuing antipsychotic medications in patients following a first episode of schizophrenia, according to a recent article in Schizophrenia Research. Investigators...
View ArticleHippocampal Reductions and Childhood Trauma in First-Episode Schizophrenia
Exposure to childhood trauma exerts disease-specific effects on hippocampal structures in patients who are women experiencing their first-episode of schizophrenia, which is consistent with increased...
View ArticleInsular Functional Dysconnectivity in Patients With First-Episode Schizophrenia
Individuals with clinical high risk for psychosis (CHR) appear to have insular functional dysconnectivity with the sensory cortex and putamen, which is similar to that observed in patients with...
View ArticleChoroid Plexus: A Sensitive Structural Biomarker for Understanding Schizophrenia
The choroid plexus may play an important role in our understanding of schizophrenia as a multisystem disorder, serving as a sensitive structural biomarker for exploring the treatment and prevention of...
View ArticleRationale Behind the Transdermal Delivery of Antipsychotic Medications
Future advancements in delivery technologies, along with their evaluation in clinical trials, might help to broaden the clinical use of transdermal drug formulations for the treatment of psychiatric...
View ArticleImplications of Menopause in Schizophrenia Treatment
Sex differences in the onset, symptoms, and course of illness in schizophrenia have long been noted. Such observations have led to the hypothesis that endogenous estrogen may have a protective effect...
View ArticleMaternal Bacterial Infection in Pregnancy Raises Offspring Psychosis Risk
Maternal bacterial infections during pregnancy are associated with an elevated risk for offspring psychotic disorders, and this association varies by the severity of the infection and the sex of the...
View ArticleManaging Refractory Psychosis in the Real World
The antipsychotic agent clozapine is underutilized in patients with continuous, complex psychosis, due in part to the medication being prescribed late in the disease course. In fact, data on...
View ArticleAssociation Between Nitrogen Dioxide and Schizophrenia Only Slightly Confounded
The association between childhood exposure to nitrogen dioxide (NO₂) and schizophrenia is only slightly confounded by increased genetic risk among individuals living in areas with higher levels of...
View Article
